Business Context and Reporting Period
Company: Pineapple Financial Inc. (PAPL)
Filing Type: Form 8-K (Current Report)
Date of Report: September 4, 2025 (Events reported September 2–4, 2025)
Reporting Period: Immediate disclosure of material definitive agreements and unregistered sales of equity securities.
The Company, an emerging growth company incorporated in Canada, announced the closing of a private placement offering to raise approximately $100 million. Proceeds are designated for a new digital asset treasury strategy focused on acquiring Injective (INJ) tokens.
Key Financial Metrics and Transaction Details
- Capital Raised: Approximately $100 million in aggregate proceeds (cash and INJ tokens).
- Offering Price: $3.80 per Subscription Receipt for most purchasers; $4.16 for certain purchasers.
- Use of Proceeds:
- $2.1 million released to the Company for legacy business expenses and working capital.
- Balance of cash proceeds and INJ tokens transferred to Asset Manager and Advisor for the Injective treasury strategy.
- Equity Issuance: Subscription Receipts exchangeable for one Common Share each upon satisfaction of escrow release conditions (including shareholder approval and SEC registration effectiveness).
- Warrants: Issuance of Meteora Warrants to Meteora Capital, LLC, exercisable into 1,045,654 Common Shares at $3.80 per share (representing 4.0% of pro forma outstanding shares).
- Future Financing (ELOC): Entered into an Equity Line of Credit (ELOC) with White Lion Capital, LLC for up to $250 million in Common Shares.
- Transaction Costs:
- Placement Agent Fee: $750,000 cash to D. Boral Capital LLC.
- ELOC Commitment Fee: INJ tokens valued at $1.5 million to White Lion Capital.
- Asset Management Fee: 1% per annum on Account Assets.
- Trading Advisory Fee: 0.25% per quarter (1.0% annual rate) on Account Equity.
Material Changes and Agreements
The filing details the entry into multiple material definitive agreements effective September 2–4, 2025:
- Private Placement: Sale of Subscription Receipts to accredited investors. Issuance of underlying Common Shares is contingent on shareholder approval and SEC registration effectiveness.
- Digital Asset Strategy: Appointment of Canary Capital Group LLC as Asset Manager and Monarq Asset Management LLC as Trading Advisor to manage the INJ treasury.
- Equity Line of Credit: Agreement with White Lion Capital allowing the Company to sell up to $250 million of shares over 24 months. Pricing is based on market VWAP with discounts ranging from 3% to 1% depending on the purchase option and volume.
- Lock-up Provisions: Purchasers in the private placement are restricted from selling securities for 12 months, with tiered release triggers if the share price reaches $7.588, $11.382, $15.176, or $18.970.
- Voting Agreement: Board members and the Injective Foundation have committed to vote in favor of the Shareholder Approval required for the transaction.
Guidance, Risks, and Contingencies
- Contingencies for Share Issuance: Common Shares will not be issued until:
- Shareholder approval is obtained.
- A registration statement (Form S-1) is declared effective by the SEC within 60 days of closing (subject to extensions).
- NYSE American listing approval is received.
- Regulatory Risks: The offering relies on exemptions from registration (Section 4(a)(2) and Rule 506(b)). Securities cannot be sold in the U.S. absent registration or exemption.
- Dilution Risk: The ELOC agreement allows for the sale of up to $250 million in additional shares, subject to a 4.99% beneficial ownership limitation for the purchaser (increasable to 9.99%).
- Market Risk: The treasury strategy exposes the Company to the volatility of the INJ digital asset.
- Management Commentary: The Company intends to use the net proceeds to launch a dedicated Injective digital asset treasury strategy.
Investor Verification Checklist
- Verify the status of the Shareholder Approval vote required to release the Subscription Receipts into Common Shares.
- Confirm the effectiveness date of the Form S-1 registration statement filed for the resale of shares.
- Monitor the Company's actual acquisition of INJ tokens and the valuation of the treasury assets post-closing.
- Review the terms of the ELOC with White Lion Capital to assess potential future dilution and pricing discounts.
- Check for any updates regarding the 12-month lock-up period and potential early release triggers based on share price performance.